Spore.Bio applies deep learning (PyTorch, Vision Transformers, Hugging Face) to biophotonic imaging—a physics-based sensor modality for microbial analysis. The stack reveals a research-heavy org (5 researchers vs. 1 engineer) still in platform-building phase, with infrastructure (AWS/GCP/Azure, Terraform, Docker) and LIMS integration suggesting they're moving beyond lab prototype toward clinical or industrial deployment. Core friction: traditional microbiology workflows are slow and constrained; Spore targets AMR (antimicrobial resistance) diagnostics as a speed-critical use case.
Spore.Bio develops microbiological diagnostic technologies combining AI and light-based sensing. Founded in 2023 and based in Paris, the company is building a biophotonics imaging analysis platform aimed at reducing diagnostic turnaround time in settings where traditional quality control and pathogen detection are bottlenecks—particularly antimicrobial resistance screening. Their projects span diagnostic software (the Spore.Labs AMR program), experiment design tooling, industrial protocol translation, and infrastructure for financial modeling and procurement. The organization is actively expanding into France and North America.
PyTorch, Vision Transformers, Hugging Face, FastAPI, PostgreSQL, Docker, Terraform, AWS/GCP/Azure, LIMS integration, and Raman spectroscopy for biophotonic sensor processing.
Biophotonics imaging analysis platform, AMR (antimicrobial resistance) diagnostics via Spore.Labs, industrial microbiology protocols, and geographic expansion into France and the US.
Other companies in the same industry, closest in size